Form 4: Vor Biopharma CEO Robert Ang Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Robert Ang, CEO of Vor Biopharma Inc., disposed of 2,751 shares of common stock on August 1, 2024, to satisfy tax withholding obligations related to the settlement of restricted stock units.
Summary
- On August 1, 2024, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 2,751 shares of common stock.
- The transaction was executed to cover tax withholding obligations associated with the settlement of restricted stock units.
- The shares were sold at a price of $0.94 per share.
- Following the transaction, Ang directly owns 807,617 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports a transaction to cover tax obligations, which is a routine event.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as officers and directors, trade in their company's stock. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of transaction: Robert Ang disposed of 2,751 shares of common stock. |
| 08/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.